0001104659-21-090300.txt : 20210708 0001104659-21-090300.hdr.sgml : 20210708 20210708171617 ACCESSION NUMBER: 0001104659-21-090300 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210707 FILED AS OF DATE: 20210708 DATE AS OF CHANGE: 20210708 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gad Thomas CENTRAL INDEX KEY: 0001753224 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38650 FILM NUMBER: 211080954 MAIL ADDRESS: STREET 1: C/O Y-MABS THERAPEUTICS, INC. STREET 2: 230 PARK AVENUE, 33RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10169 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Y-mAbs Therapeutics, Inc. CENTRAL INDEX KEY: 0001722964 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474619612 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 750 THIRD AVENUE STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-847-9841 MAIL ADDRESS: STREET 1: 750 THIRD AVENUE STREET 2: 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 4 1 tm2121612-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-07-07 0 0001722964 Y-mAbs Therapeutics, Inc. YMAB 0001753224 Gad Thomas C/O Y-MABS THERAPEUTICS, INC. 230 PARK AVENUE, SUITE 3350 NEW YORK NY 10169 1 1 0 0 See remarks Common Stock 2021-07-07 4 S 0 4000 31.8662 D 1591927 I By GAD Enterprises LLC Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2021. This transaction was executed in multiple trades at prices ranging from $31.36 to $32.59. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares. Chairman, President and Head of Business Development & Strategy /s/ THOMAS GAD 2021-07-08